| Bioactivity | Paltimatrectinib (compound I-147) is a potent tyrosine kinase inhibitor with an IC50 of <10 nM for tropomyosin kinases A (TrkA). Paltimatrectinib has the potential for cancer and inflammatory diseases[1]. | ||||||||||||
| Name | Paltimatrectinib | ||||||||||||
| CAS | 2353522-15-1 | ||||||||||||
| Formula | C20H15F5N6 | ||||||||||||
| Molar Mass | 434.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Kollol Pal, et al. 5-(2-(2,5-difluorophenyl)pyrrolidin-1 -yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as trk kinase inhibitors for treating cancer. WO2019118584A1. |